Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 62, Issue 8, 809-815
Copyright © 2005 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scott, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scott, J. D.

Therapy Update

Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients

James D. Scott

JAMES D. SCOTT, PHARM. D., is Assistant Professor of Pharmacy Practice, Western University of Health Sciences, 309 East 2nd Street, Pomona, CA 91766 (jdscott{at}westernu.edu).


Purpose. The rationale, advantages, and disadvantages of attempting to enhance the efficacy of a primary protease inhibitor (PI) with ritonavir in the management of HIV infection, especially in patients who have previously undergone highly active antiretroviral therapy (HAART), are discussed.

Summary. PIs are pivotal components of the HAART regimens used to fight HIV infection. Long-term viral suppression remains a major clinical challenge. Certain pharmacologic features of many PIs, such as their limited oral bioavailability, necessitate burdensome dosage schedules, creating a barrier to patient adherence. Compliance may be further compromised by adverse events. Any factors that undermine adherence may increase the risk that plasma drug concentrations will be suboptimal and that viral resistance and subsequent treatment failure will develop. The pharmacokinetic enhancement, or "boosting," of PI levels with low-dose ritonavir may increase PI potency and efficacy, as well as decrease the emergence of viral resistance, reduce the pill burden, and simplify administration. A number of clinical studies suggest that PI-boosted regimens are safe and effective in HIV-infected patients who have been previously treated with antiretroviral agents, but more research is needed.

Conclusion. PI boosting with ritonavir can improve PI pharmacokinetics so that potency and efficacy are increased and regimens are simplified, thereby potentially reducing antiretroviral resistance and promoting patient adherence.

Index terms: Antiretroviral agents; Blood levels; Combined therapy; Compliance; Dosage schedules; Drugs, availability; HIV infections; Patients; Pharmacokinetics; Resistance; Ritonavir; Toxicity

 



This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
E. S. Margerison, M. Maguire, D. Pillay, P. Cane, and R. C. Elston
The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication
J. Antimicrob. Chemother., April 1, 2008; 61(4): 786 - 791.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. Youle
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1195 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
P. J. Ruane, A. D. Luber, M. B. Wire, Y. Lou, M. J. Shelton, C. T. Lancaster, K. A. Pappa, and COL10053 Study Team
Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 560 - 565.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. M. Burger, S. Agarwala, M. Child, A. Been-Tiktak, Y. Wang, and R. Bertz
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3336 - 3342.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Health-System Pharmacists.